Bilgin OZTURK

Prof. Dr. Bilgin OZTURK

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
ÖKÖmer Karadaş
Ömer Karadaş
BOBilgin OZTURK
Bilgin OZTURK
RSRıza Sonkaya
Rıza Sonkaya
Background COVID-19 is a virus pandemic. According to the first obtained data, COVID-19 has defined with findings such as cough, fever, diarrhea, and fatigue although neurological symptoms of patients with COVID-19 have not been investigated in detail. This study aims to investigate the neurological findings via obtained face-to-face anamnesis and detailed neurological examination in patients with COVID-19. Methods Two hundred thirty-nine consecutive inpatients with COVID-19, supported with laboratory tests, were evaluated. Detailed neurological examinations and evaluations of all patients were performed. All evaluations and examinations were performed by two neurologists who have at least five-year experience. Results This study was carried out 239 patients (133 male + 106 female) with diagnosed COVID-19. Neurological findings were present in 83 of 239 patients (34.7%). The most common neurological finding was a headache (27.6%). D-dimer blood levels were detected to be significantly higher in patients with at least one neurological symptom than patients without the neurological symptom (p < 0.05). IL-6 level was found to be significantly higher in patients with headache than without headache (p < 0.05). Creatine kinase (CK) level was detected to be significantly higher in patients with muscle pain (p < 0.05). Conclusion Neurological symptoms are often seen in patients with COVID-19. Headache was the most common seen neurological symptom in this disease. Dizziness, impaired consciousness, smell and gustation impairments, cerebrovascular disorders, epileptic seizures, and myalgia were detected as other findings apart from the headache. It is suggested that determining these neurological symptoms prevents the diagnosis delay and helps to prohibit virus spread.

9 February 2021 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
ÖKÖmer Karadaş
Ömer Karadaş
BOBilgin OZTURK
Bilgin OZTURK
RSRıza Sonkaya
Rıza Sonkaya
BTBahar Tasdelen
Bahar Tasdelen
Aynur ÖZGEAynur ÖZGE
Aynur ÖZGE
HBHayrunnisa Bolay
Hayrunnisa Bolay

14 April 2024 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
BOBilgin OZTURK
Bilgin OZTURK
Esra TaşkıranEsra Taşkıran
Esra Taşkıran
SDSerkan Demir
Serkan Demir
MTMeryem Aslı Tuncer
Meryem Aslı Tuncer
MKMurat Kürtüncü
Murat Kürtüncü
ŞBŞuayip Birinci
Şuayip Birinci
Background: Many studies on multiple sclerosis (MS) reveal different prevalence and epidemiologic results. Objectives: In this study, we aimed to determine the epidemiologic profile of MS using official health records in Turkey. Methods: Patients diagnosed with MS from the official health data of the Ministry of Health, representing the entire population of Turkey, were included in the study. Prevalence and incidence calculations were performed using the data on gender, age, year of birth, city of residence, and year of diagnosis. Results: As a result of the study, the number of patients with the ICD code G35 was determined as 201,061 and the number of patients with this code entered at least three times was determined as 82,225. The prevalence of MS in Turkey was calculated as 96.4 per 100,000 and the female/male ratio as 2.1/1. The incidence of MS in 2022 was 6.2 per 100,000 and the mean patient age was 43.1 ± 13.3 years (female: 43.0 ± 13.1 vs male: 43.2 ± 13.7) while the mean age at first diagnosis was 34.0 ± 13.0 (female: 33.6 ± 12.6 vs male: 34.9 ± 13.7). Conclusion: The research was conducted via Official Database of Turkey, which includes population of 85 million and provides valuable insights into the prevalence and incidence rates of this chronic disease.

30 April 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
RSRıza Sonkaya
Rıza Sonkaya
BOBilgin OZTURK
Bilgin OZTURK
ÖKÖmer Karadaş
Ömer Karadaş
Coronavirus 2019 disease (Covid-19) was first seen in December 2019 and afterwards it became a pandemic. Several systemic involvements have been reported in Covid-19 patients. In this study, it was aimed to investigate the cerebrovascular hemodynamics in patients with Covid-19. The sample of this study was conducted on 20 patients hospitalized in our clinic diagnosed with Covid-19 via PCR modality and 20 healthy volunteers of similar age and sex. Bilateral middle cerebral arteries were investigated with Transcranial Doppler Ultrasonography. Basal serebral blood flow velocities and vasomotor reactivity rates were determined and compared as statistically. When patient and control groups were compared, the mean blood flow velocity was found to be higher in Covid-19 patients than the healthy volunteers and it was statistically significant (p = 0.00). The mean vasomotor reactivity rates values were found to be lower in Covid-19 group than the healthy group and also it was statistically significant (p = 0.00). An increase in cerebral basal blood velocity and a decrease in vasomotor reactivity rates in patients with Covid-19 can be considered as an indicator of dysfunction of cerebral hemodynamics in central nervous system and this can be evaluated as a result of endothelial dysfunction.

16 April 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
ZSZeynep Zeliha Sonkaya
Zeynep Zeliha Sonkaya
BOBilgin OZTURK
Bilgin OZTURK
RSRıza Sonkaya
Rıza Sonkaya
Esra TaşkıranEsra Taşkıran
Esra Taşkıran
ÖKÖmer Karadaş
Ömer Karadaş
Multiple sclerosis (MS) is one of the chronic and neurodegenerative diseases of the central nervous system (CNS). It generally affects motor, sensory, cerebellar, cognitive, and language functions. It is thought that identifying MS speech disorders using quantitative methods will make a significant contribution to physicians in the diagnosis and follow-up of MS patients. In this study, it was aimed to investigate the speech disorders of MS via objective speech analysis techniques. The study was conducted on 20 patients diagnosed with MS according to McDonald’s 2017 criteria and 20 healthy volunteers without any speech or voice pathology. Speech data obtained from patients and healthy individuals were analyzed with the PRAAT speech analysis program, and classification algorithms were tested to determine the most effective classifier in separating specific speech features of MS disease. As a result of the study, the K-nearest neighbor algorithm (K-NN) was found to be the most successful classifier (95%) in distinguishing pathological sounds which were seen in MS patients from those in healthy individuals. The findings obtained in our study can be considered as preliminary data to determine the voice characteristics of MS patients.

1 January 2019 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
BOBilgin OZTURK
Bilgin OZTURK
AÖAkçay Övünç Özön
Akçay Övünç Özön
ÖKÖmer Karadaş
Ömer Karadaş